These observations agree with known anti-inflammatory and Aβ-clearing effects of LXRα/β agonists in AD models [40–42] as well as the role of Cebpα in regulating PU.1 which maintains microglial quiescence [43]. Here, CEBPA is linked to Alzheimer disease.